Boundless Bio Inc
BOLD1.200USD
+0.040+3.45%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
26.76MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Boundless Bio Inc Unternehmen
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that addresses the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in ecDNA-enabled preclinical cancer models and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its second ecDTx, BBI-825, is an oral, selective inhibitor of ribonucleotide reductase, which is essential for ecDNA assembly and repair in cancer cells.
Unternehmensinformationen
BörsenkürzelBOLD
Name des UnternehmensBoundless Bio Inc
IPO-datumMar 28, 2024
CEOMr. Zachary D. Hornby
Anzahl der mitarbeiter64
WertpapierartOrdinary Share
GeschäftsjahresendeMar 28
Addresse10955 Alexandria Way
StadtSAN DIEGO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl92121
Telefon18587669912
Websitehttps://boundlessbio.com/
BörsenkürzelBOLD
IPO-datumMar 28, 2024
CEOMr. Zachary D. Hornby
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board
Chairman of the Board
653.48K
--
Mr. Zachary D. Hornby
Mr. Zachary D. Hornby
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Fabio Pucci, Ph.D.
Dr. Fabio Pucci, Ph.D.
Director
Director
--
--
Dr. Christian (Chris) Hassig, Ph.D.
Dr. Christian (Chris) Hassig, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Mr. David Hinkle
Mr. David Hinkle
Principal Financial Officer, Principal Accounting Officer, Treasurer
Principal Financial Officer, Principal Accounting Officer, Treasurer
--
--
Dr. James G. (Jamie) Christensen, Ph.D.
Dr. James G. (Jamie) Christensen, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert (Bob) Doebele
Mr. Robert (Bob) Doebele
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jakob Loven, Ph.D.
Dr. Jakob Loven, Ph.D.
Director
Director
--
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Director
Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board
Chairman of the Board
653.48K
--
Mr. Zachary D. Hornby
Mr. Zachary D. Hornby
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Fabio Pucci, Ph.D.
Dr. Fabio Pucci, Ph.D.
Director
Director
--
--
Dr. Christian (Chris) Hassig, Ph.D.
Dr. Christian (Chris) Hassig, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Mr. David Hinkle
Mr. David Hinkle
Principal Financial Officer, Principal Accounting Officer, Treasurer
Principal Financial Officer, Principal Accounting Officer, Treasurer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, May 14
Aktualisiert: Wed, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
14.08%
ARCH Venture Partners
12.03%
RA Capital Management, LP
9.74%
Bayer HealthCare LLC
7.22%
Nextech Invest, Ltd.
5.49%
Other
51.44%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
14.08%
ARCH Venture Partners
12.03%
RA Capital Management, LP
9.74%
Bayer HealthCare LLC
7.22%
Nextech Invest, Ltd.
5.49%
Other
51.44%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
27.63%
Venture Capital
21.89%
Investment Advisor/Hedge Fund
11.86%
Hedge Fund
8.31%
Corporation
7.22%
Individual Investor
4.18%
Research Firm
0.51%
Pension Fund
0.10%
Bank and Trust
0.08%
Other
18.22%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
128
18.31M
81.78%
-1.81M
2025Q1
129
19.49M
87.25%
+660.31K
2024Q4
119
19.41M
87.06%
+540.27K
2024Q3
106
19.47M
87.42%
+538.85K
2024Q2
87
20.07M
90.11%
+1.04M
2024Q1
53
20.35M
91.48%
+20.35M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
3.15M
14.08%
-187.23K
-5.61%
Mar 31, 2025
ARCH Venture Partners
2.69M
12.03%
--
--
Apr 25, 2025
RA Capital Management, LP
2.18M
9.74%
--
--
Mar 31, 2025
Bayer HealthCare LLC
1.62M
7.22%
--
--
Apr 25, 2025
Nextech Invest, Ltd.
1.23M
5.49%
--
--
Mar 31, 2025
Citadel Advisors LLC
830.94K
3.71%
+40.30K
+5.10%
Mar 31, 2025
Redmile Group, LLC
725.20K
3.24%
-15.00K
-2.03%
Mar 31, 2025
Sectoral Asset Management Inc.
678.57K
3.03%
--
--
Mar 31, 2025
Lim (Jonathan E)
653.48K
2.92%
--
--
Apr 25, 2025
BlackRock Institutional Trust Company, N.A.
587.40K
2.62%
-9.12K
-1.53%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
iShares Russell 2000 ETF
Anteil0%
iShares Russell 2000 Value ETF
Anteil0%
iShares Micro-Cap ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
